In some circumstances, your physician or nurse practitioner might prescribe a monthly intramuscular injection that they administer to you
Retatrutide (also referred to as LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Patients with certain GLP1R variants may achieve therapeutic benefit at lower doses, while others require higher exposure for equivalent weight lossand mismatched dosing in either direction increases overdose or inefficacy risk
Epigenetic factors, including DNA methylation, histone modifications, and microRNAs, further modulate BCMO1 expression, influenced by diet, inflammation, and stress [22]
M., Nikooienejad, A., Bray, R., Karber, K